Pharma major Jubilant Life Sciences on Tuesday reported net revenues of Rs 890 crore for the January-March quarter of the last fiscal led by robust growth of its products division. The company’s net profit during the quarter stood at R62 crore.
“In financial year 2011 the company has recorded a good revenue growth in products business driven by a robust volume growth of 16% across products. However, the growth in service business is muted due to a one-time revenue opportunity in previous year," said Shyam S Bhartia, chairman & managing director and Hari S Bhartia, co-chairman & managing director, Jubilant Life Sciences Ltd.
Net revenues, when calculated by excluding the one-time gains from H1N1 (viral) outbreak that happened last year, grew by 11% during the quarter.
“In FY2012, we expect a robust sales growth and better margins across all the businesses on increased capacity utilisation, commissioning of new plants, innovation led new launches and expansion of market geographies,” said Shyam S Bhartia and Hari S Bhartia.